Literature DB >> 8583476

Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders.

F Fyhrquist1, K Metsärinne, I Tikkanen.   

Abstract

Angiotensin II (Ang II) raises blood pressure (BP) by a number of actions, the most important ones being vasoconstriction, sympathetic nervous stimulation, increased aldosterone biosynthesis and renal actions. Other Ang II actions include induction of growth, cell migration, and mitosis of vascular smooth muscle cells, increased synthesis of collagen type I and III in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. These actions are mediated by type 1 Ang II receptors (AT1), and may be blocked by losartan, a specific blocker of AT1 receptors. In particular, studies employing losartan have shown that Ang II is an important contributor to BP regulation and plays a significant role in hypertension and in the pathophysiology of vascular damage during the course of hypertension. Ang II is also involved in the process of atherosclerosis and in remodelling and repair processes of the myocardium following myocardial infarction. Finally, increased Ang II is an important part of neurohumoral activation in heart failure. Exciting new discoveries concerned with polymorphisms of genes coding for angiotensin converting enzyme (ACE) and angiotensinogen suggest that Ang II may be genetically associated with increased risk for myocardial infarction, hypertension and left ventricular hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8583476

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  38 in total

Review 1.  Prehypertension: Underlying pathology and therapeutic options.

Authors:  Sulayma Albarwani; Sultan Al-Siyabi; Musbah O Tanira
Journal:  World J Cardiol       Date:  2014-08-26

2.  High-salt diet during pregnancy and angiotensin-related cardiac changes.

Authors:  Yang Ding; Juanxiu Lv; Caiping Mao; Huiying Zhang; Aiqing Wang; Liyan Zhu; Hui Zhu; Zhice Xu
Journal:  J Hypertens       Date:  2010-06       Impact factor: 4.844

3.  Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling.

Authors:  Yeshitila Gebremichael; Gezim Lahu; Majid Vakilynejad; K Melissa Hallow
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-11-16       Impact factor: 2.745

4.  The role of DNA methylation and histone modifications in blood pressure: a systematic review.

Authors:  Valentina Gonzalez-Jaramillo; Eliana Portilla-Fernandez; Marija Glisic; Trudy Voortman; Wichor Bramer; Rajiv Chowdhury; Anton J M Roks; A H Jan Danser; Taulant Muka; Jana Nano; Oscar H Franco
Journal:  J Hum Hypertens       Date:  2019-07-25       Impact factor: 3.012

Review 5.  Angiotensin II-related hypertension and eye diseases.

Authors:  Pablo Jesus Marin Garcia; Maria Encarna Marin-Castaño
Journal:  World J Cardiol       Date:  2014-09-26

6.  Quality Control of Therapeutic Peptides by 1H NMR HiFSA Sequencing.

Authors:  Mary P Choules; Jonathan Bisson; Wei Gao; David C Lankin; James B McAlpine; Matthias Niemitz; Birgit U Jaki; Scott G Franzblau; Guido F Pauli
Journal:  J Org Chem       Date:  2019-02-22       Impact factor: 4.354

7.  Angiotensin II Causes Neuronal Damage in Stretch-Injured Neurons: Protective Effects of Losartan, an Angiotensin T1 Receptor Blocker.

Authors:  P M Abdul-Muneer; Saurav Bhowmick; Nicholas Briski
Journal:  Mol Neurobiol       Date:  2017-11-08       Impact factor: 5.590

8.  Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors.

Authors:  Andrea Linares; Leena E Couling; Eduardo J Carrera; Robert C Speth
Journal:  J Vis Exp       Date:  2016-06-07       Impact factor: 1.355

9.  Associations of fractalkine receptor (CX3CR1) and CCR5 gene variants with hypertension, diabetes and atherosclerosis in chronic renal failure patients undergoing hemodialysis.

Authors:  Binnur Bagci; Gokhan Bagci; Can Huzmeli; Ilhan Sezgin; Ozturk Ozdemir
Journal:  Int Urol Nephrol       Date:  2016-04-27       Impact factor: 2.370

10.  Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study.

Authors:  Nikolaos Tzemos; Pitt O Lim; Thomas M MacDonald
Journal:  Cardiovasc Ther       Date:  2009-07-14       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.